BioCentury | May 19, 2017
Financial News

TetraGenetics receives JDRF T1D Fund investment

...mAbs targeting potassium channel Kv1.3 (KCNA3) to treat Type I diabetes. TetraGenetics Inc. , Arlington, Mass. Alicia Parker TetraGenetics Inc....
BioCentury | May 2, 2017
Financial News

Tetragenetics gets JDRF investment

...said. Tetragenetics is developing mAbs targeting potassium channel Kv1.3 (KCNA3) to treat Type I diabetes. Tetragenetics...
...Israel) and islet regeneration company Semma Therapeutics Inc. (Cambridge, Mass.) (see BioCentury, Jan. 27) . Becky Simon JDRF Tetragenetics Inc. Potassium...
BioCentury | Jun 6, 2016
Company News

Tetragenetics, Theranyx deal

...The partners said they will focus on pain and cancer indications. The companies will use Tetragenetics’...
...Therabody development platform, which generates functional antibody fragments. The companies declined to disclose financial terms. Tetragenetics Inc....
BioCentury | Apr 2, 2013
Company News

Tetragenetics in pair of protein expression deals

...that would be difficult to make in standard expression systems. Under its deal with Amgen, Tetragenetics...
...jointly develop antibodies against the target. Amgen was off $0.20 to $102.31 on Monday. Separately, Tetragenetics...
BioCentury | Apr 1, 2013
Company News

Tetragenetics, Bill & Melinda Gates Foundation infectious news

...received an $824,000 Phase II grant through the Grand Challenges Explorations initiative of the foundation. Tetragenetics...
...thermophila that display heterologous proteins on their surfaces, creating stimulatory structures for the immune system. Tetragenetics Inc....
BioCentury | Apr 1, 2013
Company News

Amgen, Tetragenetics, Pfizer deal

...access" and exclusive research rights to an undisclosed surface antigen drug target selected by Amgen. Tetragenetics...
...way." The partners declined to provide financial details. Separately, Tetragenetics partnered with Pfizer to use Tetragenetics'...
...exclusive license under the deal for use of the ion channel preparations provided by Tetragenetics. Tetragenetics...
BioCentury | Apr 1, 2013
Product Development

Producing provocative proteins

...discoveries from the same platform to produce antigens for vaccines. Under its deal with Amgen, Tetragenetics...
...The partners then will jointly develop antibodies against the target. In its deal with Pfizer, Tetragenetics...
...Amgen and Pfizer deals, Kahn said Tetragenetics has about half a dozen additional undisclosed partnerships. Tetragenetics...
Items per page:
1 - 7 of 7
BioCentury | May 19, 2017
Financial News

TetraGenetics receives JDRF T1D Fund investment

...mAbs targeting potassium channel Kv1.3 (KCNA3) to treat Type I diabetes. TetraGenetics Inc. , Arlington, Mass. Alicia Parker TetraGenetics Inc....
BioCentury | May 2, 2017
Financial News

Tetragenetics gets JDRF investment

...said. Tetragenetics is developing mAbs targeting potassium channel Kv1.3 (KCNA3) to treat Type I diabetes. Tetragenetics...
...Israel) and islet regeneration company Semma Therapeutics Inc. (Cambridge, Mass.) (see BioCentury, Jan. 27) . Becky Simon JDRF Tetragenetics Inc. Potassium...
BioCentury | Jun 6, 2016
Company News

Tetragenetics, Theranyx deal

...The partners said they will focus on pain and cancer indications. The companies will use Tetragenetics’...
...Therabody development platform, which generates functional antibody fragments. The companies declined to disclose financial terms. Tetragenetics Inc....
BioCentury | Apr 2, 2013
Company News

Tetragenetics in pair of protein expression deals

...that would be difficult to make in standard expression systems. Under its deal with Amgen, Tetragenetics...
...jointly develop antibodies against the target. Amgen was off $0.20 to $102.31 on Monday. Separately, Tetragenetics...
BioCentury | Apr 1, 2013
Company News

Tetragenetics, Bill & Melinda Gates Foundation infectious news

...received an $824,000 Phase II grant through the Grand Challenges Explorations initiative of the foundation. Tetragenetics...
...thermophila that display heterologous proteins on their surfaces, creating stimulatory structures for the immune system. Tetragenetics Inc....
BioCentury | Apr 1, 2013
Company News

Amgen, Tetragenetics, Pfizer deal

...access" and exclusive research rights to an undisclosed surface antigen drug target selected by Amgen. Tetragenetics...
...way." The partners declined to provide financial details. Separately, Tetragenetics partnered with Pfizer to use Tetragenetics'...
...exclusive license under the deal for use of the ion channel preparations provided by Tetragenetics. Tetragenetics...
BioCentury | Apr 1, 2013
Product Development

Producing provocative proteins

...discoveries from the same platform to produce antigens for vaccines. Under its deal with Amgen, Tetragenetics...
...The partners then will jointly develop antibodies against the target. In its deal with Pfizer, Tetragenetics...
...Amgen and Pfizer deals, Kahn said Tetragenetics has about half a dozen additional undisclosed partnerships. Tetragenetics...
Items per page:
1 - 7 of 7